Abstract
Purpose: To propose an improved chemical skeleton whose scaffolds could be used for the design of future thymidylate synthase (TS)-inhibitors against rheumatoid arthritis.
Methods: The drug discovery platform, 'MCULE', was employed for inhibitor-screening. The 'methotrexate-interaction site' in the crystal (PDB ID 5X66) was used as a target. One 'RO5 violation' was permitted. A maximum of '10 rotatable bonds' and '100 diverse molecules' were also allowed in the protocol. The 'threshold similarity cut off' was 0.7. The input values describing the remaining parameters were kept as 'default'. The 'Open Babel Linear Fingerprint' was used for the analyses of molecular descriptors, followed by ADME-check.
Results: 4-(4-Methyl-1-piperazinyl)-2-phenyl[1]benzofuro[3,2-d]pyrimidine corresponding to the MCULE ID-7590816301-0-93 exhibited the overall best binding with TS. The free energy of binding was -8.6 kcal/mol. A total of 17 amino acid residues were significant for the binding interactions. Importantly, 9 residues were common to methotrexate binding. It satisfied pertinent ADME conditions.
Conclusion: 4-(4-Methyl-1-piperazinyl)-2-phenyl[1]benzofuro[3,2-d]pyrimidinemay emerge as a potent seed molecule for TS-inhibitor design in the context of rheumatoid arthritis. It has satisfied pertinent ADME features. However, there is need for further wet laboratory validation.